Intrathecal Mesenchymal Stem Cells in Progressive MS: The SMART-MS Trial

This randomized, double-blind study investigated the potential for autologous mesenchymal stem cells (MSCs) to repair neurological damage in patients with progressive multiple sclerosis. Using an intrathecal administration route to bypass the blood-brain barrier, researchers monitored nerve conduction speeds and brain volume changes over a year. The results failed to demonstrate a significant neuroregenerative effect, as the primary measures of electrical signal latency showed no improvement compared to the placebo group. While cerebrospinal fluid proteomics suggested some anti-inflammatory activity, these molecular shifts were overshadowed by safety concerns, including localized spinal inflammation and nerve root clumping. Ultimately, the trial concluded that this specific stem cell therapy does not currently provide a viable solution for functional repair in MS. The authors suggest that future applications of this delivery method must be approached with extreme caution due to the risk of serious adverse events.